Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site

Blood

Volumn 99, Issue 6, 2002, Pages 2241-2244

  Tentori, Lucio ^a,b,c,d   Leonetti, Carlo ^a,b,c,d   Scarsella, Marco ^a,b,c,d   D'Amati, Giulia ^a,b,c,d   Portarena, Ilaria ^a,b,c,d   Zupi, Gabriella ^a,b,c,d   Bonmassar, Enzo ^a,b,c,d   Graziani, Grazia ^a,b,c,d  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXY 2 METHYL 4(3H) QUINAZOLINONE; 8 HYDROXY 2 METHYLQUINAZOLIN 4 YL; ENZYME INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD DISEASE; BRAIN LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CONTROLLED STUDY; DNA METHYLATION; DRUG EFFICACY; FRACTIONATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR GROWTH;

EID: 0037085761     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.6.2241     Document Type: Article

References (25)

1. Multi-center phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse: Temodal Brain Tumor Group
2. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme
3. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
4. Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma
5. 6-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by temozolomide
6. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea
7. Involvement of the mismatch repair system in temozolomide-induced apoptosis
8. Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds
9. Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components
10. Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells
11. Potentiation of temozolomide-induced cytotoxicity: A comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors
12. The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy
13. 6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines
14. Intracerebral adoptive immuno-therapy of a murine lymphoma antigenically altered by drug treatment in vivo
15. Activity of temozolomide in the treatment of central nervous system tumor xenografts
16. O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts
17. 6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide
18. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multi-drug resistance
19. Nonparametric estimation from incomplete observations
20. Tissue distribution and antitumor activity of topotecan delivered by intra-cerebral clysis in a rat glioma model
21. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and-proficient colon cancer cells to methylating agents
22. 6-benzylguanine and its role in chemotherapy
23. 6-benzylguanine
24. 6-arkylguanine-DNA alkyltransferase activity